Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting
NCT06170788Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
A Study of Mirdametinib in People With Central Nervous System TumorsRecruiting
NCT07539441Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Central Nervous System Tumors · Glioma
United States
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)Recruiting
NCT07247110Phase 1Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Australia, Canada, Chile, Israel +2 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Recruiting
NCT07419295Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Argentina, Australia, Belgium, Brazil +11 more
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Recruiting
NCT07519772Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
United States, Argentina, Australia, Canada, Chile +8 more
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaActive Not Recruiting
NCT04069273Phase 2Updated Sep 3, 2026
Sponsor: Harry H Yoon
Gastric Cancer · GastroEsophageal Cancer · Adenocarcinoma
United States
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting
NCT06824467Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Recruiting
NCT07318558Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Neoplasms · Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Recruiting
NCT05139017Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
DLBCL · Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Brazil, Canada +21 more
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Recruiting
NCT06353386Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostatic Neoplasms, Castration-Resistant
United States, Australia, Canada, Chile, Colombia +15 more
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Recruiting
NCT06445972Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +6 more
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Recruiting
NCT06395103Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma
United States, Australia, Belgium, Brazil, Canada +18 more
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)Terminated
NCT04246177Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
United States, Australia, Brazil, Chile, China +22 more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Recruiting
NCT06136624Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostate Cancer Metastatic
United States, Argentina, Australia, Austria, Brazil +31 more
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Recruiting
NCT07570173Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia
Denmark, Greece, Israel, Italy, Japan +3 more
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Recruiting
NCT07489495Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Argentina, Australia, Brazil, Chile +13 more
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Recruiting
NCT07405164Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Von Hippel-Lindau Disease · Malignant Neoplasms
United States, Australia, Belgium, Brazil, Canada +17 more
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting
NCT06966700Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +34 more
A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)Active Not Recruiting
NCT07661108Phase 1Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Recruiting
NCT06422143Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · NSCLC
United States, Argentina, Austria, Brazil, Canada +21 more
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompleted
NCT03674567Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: RAPT Therapeutics, Inc.
Advanced Cancer
United States, Australia, Hong Kong, South Korea, Taiwan +1 more
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)Not Yet Recruiting
NCT07801027Phase 4Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Neoplasm Malignant · Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma · Biliary Tract Carcinoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive Not Recruiting
NCT04657991Phase 3Updated Sep 3, 2026
Sponsor: Pfizer
Melanoma
United States, Argentina, Austria, Belgium, Brazil +22 more
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)Recruiting
NCT07222488Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer · Urinary Bladder Neoplasms
United States, Austria, Belgium, Canada, France +7 more

Previous page Next page